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The isolated @chain of human complement factor C3 (C3& was fragmented by cyanogen bromide. Nine 
fragments were defined by gel filtration and high-pressure liquid chromatography, and characterized with 
respect to their M,, amino acid composition and N-terminal amino acid sequence. Approx. 30% of the 
primary structure of C3fi was determined. Alignment of the 3 N-terminal fragments allowed determination 
of 61 of the amino terminal residues of C3fl. This region demonstrated 40% homology with the sequence 
in the N-terminal segment of the a-chain of the cobra venom factor. 
Complement Human C3 Cyanogen bromide fragmentation Sequence Homology 
1. INTRODUCTION 
The complement factor C3 is one of the central 
components in the complement cascade. Func- 
tionally, C3 is of crucial importance for activation 
of both the classical and alternative pathway. The 
molecule is composed of two polypeptide chains 
designated (Y (Mr 120000) and ,& (Mr 75000) [1,2], 
which are combined by disulfide bridges and non- 
covalent forces. 
In addition to the interaction with several other 
complement proteins, activated C3 (C3b) is also 
able to elicit a covalent bond to other molecules, 
and to attach to cell receptors (review [3]). Many 
of these functions are closely associated with the a- 
chain (C3a). Concerning the &chain (C3p), very 
little is known about its structure and virtually 
+ Present address: Scripps Clinic and Research Founda- 
tion, 10666 North Torrey Pines Rd, La Jolla, CA 
92037, USA 
* To whom correspondence should be addressed 
Abbreviations: DITC, p-phenylenediisothiocyanate; 
HPLC, high-pressure liquid chromatography; C3cu, (Y- 
chain of human C3; C3fi, P-chain of human C3; CVF, 
cobra venom factor; CVFcu, a-chain of CVF 
nothing about its function. The M,, amino acid 
composition and a short N-terminal sequence have 
been published [4,5]. In contrast to C3&, C3,8 is 
fairly resistant to proteolytic enzymes [1,4,6]. To 
understand the functional role of C3,8 further 
knowledge about the structure is necessary. We 
describe here the preparation and characterization 
of cyanogen bromide fragments from C3,8. 
2. MATERIALS AND METHODS 
2.1. Materials 
The following materials were purchased: 
Sephadex G-75 superfine, Sephadex G-200, 
QAE-Sephadex A-50, SP-Sephadex C-50 (Phar- 
macia, Uppsala); controlled pore glass (CPG 10) 
and 3-aminopropyltriethoxysilane (Serva, Heidel- 
berg); DITC (Rathburn, Walkerburn, England); 
guanidine hydrochloride Aristar@ (BDH, Poole, 
England); phenylmethylsulfonyl fluoride (Sigma, 
St. Louis). 
2.2. Isolation of human C3 
Fresh frozen plasma was thawed and 
phenylmethylsulfonyl f uoride was added to a con- 
centration of 0.25 mg/ml. The plasma was ad- 
sorbed twice with QAE-Sephadex A-50 (15%) 
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v/v) under continuous stirring for 1 h at 4-6°C. 
The adsorbed gel portions were then layered on top 
of a thin bed of fresh QAE-Sephadex A-50 in 
separate columns and washed with20 mM Tris- 
HCl buffer with 0.11 M NaCl and 2 mM EDTA 
(pH 7.0). C3 was eluted by 0.2 M NaCl. C3 was 
assayed in the column effluent by hemolytic titra- 
tion [7,8]. The C3 pools were combined and dialys- 
ed against a buffer of 20 mM phosphate with 
40 mM NaCl (pH 6). Insoluble material was 
removed by centrifugation and the supernatant ap- 
plied on an SP-Sephadex C-50 column (5 x 
30 cm) equilibrated in the same buffer. C3 was 
separated from C5 and factor H by elution with a 
gradient composed of 1.5 1 of starting buffer vs 
1.5 1 of 20 mM phosphate buffer with 0.1 M NaCl 
(pH 7.5). Final purification of C3 was achieved by 
gel filtration on Sephadex G-200 in 0.02 M 
phosphate buffer with 0.15 M NaCl (pH 7.2). 
2.3. Isolation of the P-chain of human C3 (C3p! 
Purified human C3 was treated with 
methylamine as in [8] and then reduced and car- 
boxymethylated [9]. The material was dialysed 
against 1.0 M acetic acid, lyophilized and 
redissolved in 0.1 M pyrophosphate with 6 M 
guanidinium hydrochloride. Maleylation was car- 
ried out essentially as in [lo], and the maleylated 
C3 was transferred to 20 mM Tris-HCl with 
0.25 M NaCl (pH 8.0). C3P was obtained by 
chromatography on a DEAE-Sephacel column 
(2.5 x 35 cm) equilibrated in the same buffer and 
eluted by applying a gradient of 500 ml starting 
buffer vs 500 ml of 20 mM Tris buffer with 
0.75 M NaCl. The prepared C3fl was found to be 
devoid of a-chain material as found by 
polyacrylamide gel electrophoresis in sodium 
dodecyl sulfate (SDS-PAGE), amino acid analysis 
and immunodiffusion. Unblocking of the maleyl 
groups of C3,& was achieved in 0.1 M glycine buf- 
fer (pH 3.0). 
Full details of the separation of C3, C4, CS, fac- 
tor H and the C3 chains will be published 
elsewhere. 
2.4. Preparation of cyanogen bromide fragments 
of C3P 
Lyophilized C3fl (0.6 pmol) was dissolved in 
7 ml of 100% formic acid, which was subsequently 
diluted with 3 ml distilled water. Digestion was 
performed at room temperature with 0.3 mmol 
cyanogen bromide for 24 h, whereafter the sample 
was diluted with 50 vols of distilled water and 
lyophilized. It was then suspended in 10 ml of 50% 
acetic acid. Insoluble material was collected by 
centrifugation at 15000 x g (pool 2). The superna- 
tant (pool 1) was chromatographed on a 4.9 cm2 x 
100 cm column of Sephadex G-75 superfine in 
1 .O M acetic acid at a flow rate of 10 ml/h, and the 
effluent was monitored at 280 nm. 
2.5. M, determination of cyanogen bromide 
fragments 
M, determinations were performed by 
chromatography on TSK 2000 (7.5 x 600 mm) in 
6 M guanidinium hydrochloride in 25 mM am- 
monium acetate (pH 6.5), with a flow rate of 
33 &min. The column eluate was monitored at 
230 nm. Reduced and carboxymethylated proteins 
and cyanogen bromide fragments from 
cytochrome c were used as standards and the M, 
values were calculated as in [l 11. 
2.6. Amino acid analysis and sequence 
determination 
Amino acid analysis was performed as in [12]. 
Manual Edman degradation was done by the direct 
phenylthiohydantoin method [ 131. Automatic Ed- 
man degradation on solid phase was performed on 
an LKB 4020 solid-phase peptide sequencer. 
Cyanogen bromide peptides with a C-terminal 
homoserine were immobilized on aminopropyl 
glass as in [14]. Peptides without C-terminal 
homoserine were coupled to DITC-glass [ 151. The 
PTH amino acids were identified by HPLC on a 
Nucleosil ODS column (4 x 300 mm) in 6 mM 
sodium acetate buffer (pH 4.9), using a gradient of 
acetonitrile, except for PTH-valine and PTH- 
methionine which were determined by back 
hydrolysis [ 161. 
3. RESULTS AND DISCUSSION 
The chromatogram of pool 1 on Sephadex G-75 
is shown in fig.1. The peaks were analysed by 
amino acid analysis (table l), and manual and 
automatic Edman degradation. Three cyanogen 
bromide fragments were obtained in homogeneous 
form: CN2, CN3 and CN8. Their N-terminal se- 
quences are shown in fig.2. CN8 was completely 
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sequenced, 27 residues were determined in CN2 
and 41 residues in CN3. 
The third peak contained 3 different fragments 
(CN4, CNS, CN6), yielding a triple sequence on 
automatic Edman degradation. However, by 
separate analyses of the ascending and descending 
parts of the peak (see fig. 1) double sequences were 
obtained for each analysis, one of which was domi- 
nant in each pool. By determination of the 
recovery of the individual PTH-amino acids it was 
50 100 150 200 
Fractmn 
Fig.1. Gel filtration on Sephadex G-75 superfine of the 
acid-soluble cyanogen bromide peptides of human C3@ 
(pool 1) in 1.0 M acetic acid. The column eluate was 
monitored at 280 nm. Pooling was performed as 
indicated. 
found that the ascending part contained 60-70% 
of CN4 and the descending part 60-70% of CN6. 
The sequence of CN6 was completed with a C- 
terminal homoserine in position 30, while the se- 
quence of CN4 could be determined up to residue 
3 1. The PTH-amino acids in the triple sequence in 
the central part of the peak occurred in approx- 
imately equimolar proportions, therefore the se- 
Table 1 
Amino acid composition of C3j3 and cyanogen bromide fragments 
Trpa 
Lys 
His 
Arg 
Cysb 
Asx 
Thr 
Ser 
Glx 
Pro 
Gly 
Ala 
Val’ 
Met/Hse 
Be’ 
Leu 
Tyr 
Phe 
CN2 CN3 CN4 CN6 
N.D. N.D. 0.4 N.D. 
4.8 5.6 1.7 2.0 (3) 
1.9 4.2 0.6 0.7 (1) 
6.0 1.2 1.3 1.5 (1) 
0.6 0.1 0.1 0.3 
9.3 6.6 5.7 2.0 
9.6 6.9 1.6 2.3 (3) 
8.0 3.5 3.6 2.3 (2) 
13.7 6.0 5.8 3.3 (3) 
7.8 2.3 2.4 2.9 (4) 
6.8 3.2 2.3 1.9 (2) 
6.2 4.4 0.7 1.6 (1) 
9.4 9.3 3.7 2.3 (1) 
1.0 0.6 0.4 0.4 (1) 
2.9 0.7 2.0 1.6 (3) 
10.1 7.0 5.8 2.3 
2.3 0.8 0.9 1.4 (2) 
1.9 1.7 0.7 1.2 (2) 
CN7a 
N.D. 
0.4 
0.3 
1.5 (1) 
- 
1.2 (1) 
1.9 (2) 
1.8 (2) 
2.4 (3) 
1.0 (1) 
0.2 
0.6 
- 
0.4 (1) 
2.3 (3) 
2.0 (2) 
1.7 (1) 
- 
CN7b 
N.D. 
1.0 (1) 
0.8 (1) 
1.8 (2) 
- 
1.0 (1) 
0.9 (1) 
0.4 
0.9 (1) 
_ 
0.4 
1.8 (2) 
0.2 
0.4 (1) 
1.7 (2) 
1.0 (1) 
2.7 (3) 
- 
CN8 CN9 C3P 
N.D. N.D. 3.2 
- - 38.7 
- - 9.3 
0.2 - 29.0 
- - 4.4 
1.1 (1) 0.4 51.2 
0.2 - 46.6 
0.5 0.9 (1) 45.5 
0.4 0.4 79.6 
1.0 (1) 1.0 (1) 41.1 
0.3 0.3 45.5 
0.2 - 30.9 
0.3 - 68.7 
0.6 (1) 0.6 (1) 11.1 
- - 29.4 
1.0 (1) 0.3 57.5 
- - 24.4 
0.9 (1) 0.3 25.7 
Residues 102.3d 62.8d 39.7d (30) (17) (16) (5) (3) 641.5 
a Determined after hydrolysis in 3 M toluene-p-sulfonic acid 
b Determined as carboxymethylcysteine 
’ Determined after hydrolysis for 72 h 
d Estimated after gel filtration in 6 M guanidinium hydrochloride 
Figures within parentheses represent numbers of amino acid residues estimated from amino acid analyses and sequence 
determinations. N.D., not determined 
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CN2 VFVTNPDGSPAYRVPVAVQGEDTVQSL 
CN3 VLEAHDAQGDVPVTVTVHDFPGKKLVLSSEKTVLTPATNQQ 
CN4 XNIENPEGIPVKQDSLSSQ!!QLGVLPLSWDI 
CNsb) XALPYSTVGNSNNYLHL 
CN6 XQAERSGIPIVTSPYQIHFTKTPKYFKPGM 
CN7a YSIITPNILPLESEETM 
CN7b DRAHEAKIRYYTYLIM 
CN8 PFDLM 
CN9 SPM 
Fig.2. N-terminal amino acid sequence of cyanogen bromide fragments of C3fl. X denotes that the N-terminal amino 
acid could not be ascertained. Manual Edman degradation of a pool containing CN4, CN5 and CN6 yielded only PTH- 
valine. The sequence of CN5 was deduced from the same pool, whereby the sequences of CN4 and CN6 were subtracted 
from the obtained triple sequence. 
quence of CN5 was deduced up to step 15 by sub- 
tracting the sequences of CN4 and CNS. 
Manual Edman degradation revealed that the 
fourth peak contained two fragments (CN7a and 
CN7b). These were further purified with HPLC on 
a 5~ Lichrosorb RP8 column (4 x 250 mm), 
operated at 35°C with a linear gradient of 
acetonitrile in 0.10% trifluoroacetic acid (not 
shown). The two fragments were well separated 
from each other as determined by amino acid 
analysis and manual Edman degradation. The 
completed sequences of the fragments are shown in 
fig.2. 
Three amino acids in equimolar proportions 
were detected by amino acid analysis in the total 
volume eluate of the G-75 column: homoserine, 
proline and serine (CN9, fig. 1). By manual Edman 
degradation PTH-serine was obtained, suggesting 
the sequence Ser-Pro-Hse of the peptide. This se- 
quence agrees with the reported N-terminal se- 
quence of C3fl [5], thus CN9 most probably 
represents the N-terminal cyanogen bromide 
fragment. 
Chromatography of cyanogen bromide-digested 
C3p on TSK 2000 in guanidine hydrochloride is 
shown in fig.3A. For comparison, pool 2 (acid- 
insoluble material) was run in the same way 
(fig.3B), and 3 peaks were generated (in addition 
to the total volume). These peaks coincide with the 
first 3 eluting peaks of the total digest (fig.3A), 
and represent most probably the acid-insoluble 
60 
ELUTION VOLUME 
Fig.3. Chromatography in 6 M guanidinium 
hydrochloride on TSK 2000. The column eluate was 
monitored at 230 nm. V,, void volume; vl, total 
volume. (A) Cyanogen bromide-digested C3p. (B) Acid- 
insoluble fragments from cyanogen bromide-digested 
c3p (pool 2). 
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CVF# 
20 
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Fig.4. Comparison of the N-terminal amino sequence of the a-chain of CVF and human C3@. The N-terminal sequence 
of CVFcr is reported in [13] and the amino terminal sequence of C3P is obtained by alignment of cyanogen bromide 
peptides CN9, CN7a and CN3. Identical residues in the two chains are boxed in. The numbers refer to amino acid 
residues in C3p; the N-terminal amino acid in CVFcv is located at no.2. 
cyanogen bromide fragments. Since C3,& contains 
11 methionines, .as has been found by us (table 1) 
and others [4,5], 12 cyanogen bromide fragments 
would be expected, suggesting 3 acid-insoluble 
fragments besides the 9 acid-soluble fragments, 
which would agree with the number of peaks ob- 
tained in fig.3B. The elution positions of CN2, 
CN3, CN4-6 and CN7a/b were estimated after 
comparison with the elution pattern of the 
fragments from Sephadex G-75. The M, values ob- 
tained were 11300 (CN2), 6800 (CN3), 4300 
(CN4-6) and 1400 (CN7a/b). The acid-soluble 
fragments account for approx. 50% of the i’k& of 
C3@. All contained homoserine, which indicates 
that the C-terminal fragment of C3fl might be 
found among the acid-insoluble fragments. None 
contained significant amounts of cysteine, sug- 
gesting that all the cysteine residues are located in 
the acid-insoluble fragments. 
From the reported N-terminal amino acid se- 
quence of C3fl [5], the alignment CN9-CN7a can 
be made. If this combined sequence is compared 
with the reported N-terminal sequence of the 
chains of CVF (91, a homology of 40% is found 
between the first 19 amino acid residues of the cy- 
chain in CVF (CVFo), and residues 2-20 of C3p 
(fig.4). This confirms the structural relationships 
between C3fl and CVFa as suggested by im- 
munological methods [ 171. Furthermore, residues 
20-25 in CVFa are so similar to the amino ter- 
minal residues in CN3 that the latter can be as- 
sumed to represent the third cyanogen bromide 
fragment from the amino terminal end of C3p, 
which makes it possible to deduce the N-terminal 
amino acid sequence of C3fl up to residue 61. We 
could not detect any sequence homology between 
our C3P fragments and the amino terminal 
sequences of the other two chains of CVF (CVFfl 
and CVFy), which is in accordance with the state- 
ment that these chains are immunologically related 
to C3cu. Since the a-chain of CVF most probably 
corresponds to the&chain of cobra C3 [17] further 
studies of the primary structure of CVFcv and 
human C3fl will give valuable information about 
the phylogenetic development of the C3 molecule. 
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